Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 24, Issue 1, 2006, Pages 31-37

  Dombrecht, Evelyne J ^a   Aerts, Nicolaas E ^a   Schuerwegh, Annemie J ^a   Hagendorens, Margo M ^a   Ebo, Didier G ^a   Van Offel, Jan F ^a   Bridts, Chris H ^a   Stevens, Wim J ^a   De Clerck, Luc S ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Anti TNF therapy; Dendritic cells; Regulatory T cells; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CELL SEPARATION; CYTOKINES; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645059178     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. BAYRY J, THIRION M, DELIGNAT S et al.: Dendritic cells and autoimmunity. Autoimmun Rev 2004; 3: 183-7.
2. MOSER M, MURPHY KM: Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000; 1: 199-205.
3. RISSOAN MC, SOUMELIS V, KADOWAKI N et al.: Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283:1183-6.
4. SCHULZE-KOOPS H, KALDEN JR: The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001; 15: 677-91.
5. BAECHER-ALLAN C, BROWN JA, FREEMAN GJ, HAFLER DA: CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-53.
6. SAKAGUCHI S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101: 455-8.
7. SHEVACH EM: Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000; 18: 423-49.
8. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
9. ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-90.
10. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
11. MAINT RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
12. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
13. SCHUERWEGH AJ, Van OFFEL JF, STEVENS WJ, BRIDTS CH, De CLERCK LS: Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford) 2003; 42: 541-8.
14. DE MIGUEL S, JOVER JA, VADILLO C, JUDEZ E, LOZA E, FERNANDEZ-GUTIERREZ B: B cell activation in rheumatoid arthritis patients under infliximab treatment. Clin Exp Rheumatol 2003; 21: 726-32.
15. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
16. PREVOO ML, 'T HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
17. DEN BROEDER AA, CREEMERS MC, van GESTEL AM, van RIEL PL: Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology (Oxford) 2002; 41: 638-42.
18. ALMEIDA J, BUENO C, ALGUERO MC et al.: Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineagecells. Clin Exp Immunol 1999; 118: 392-401.
19. HAGENDORENS MM, EBO DG, SCHUERWEGH AJ et al.: Differences in circulating dendritic cell subtypes in cord blood and peripheral blood of healthy and allergic children. Clin Exp Allergy 2003; 33: 633-9.
20. HAGENDORENS MM, EBO DG, BRIDTS CH, DE CLERCK LS, STEVENS WJ: Flow cytometrical determination of regulatory cytokines (IL- 10, IL- 12) and circulating dendritic cell cytokines in allergic asthmatic children. Cytokine 2004; 26: 82-8.
21. LIU MF, WANG CR, FUNG LL, WU CR: Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004; 59: 198-202.
22. LANDE R, GIACOMINI E, SERAFINI B et al.: Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J Immunol 2004; 173: 2815-24.
23. Van KRINKS CH, MATYSZAK MK, GASTON JS: Characterization of plasmacytoid dendritic cells in inflammatory arthritis synovial fluid. Rheumatology (Oxford) 2004; 43: 453-60.
24. CAVANAGH LL, BOYCE A, SMITH L et al.: Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res Ther 2005; 7: R230-R240.
25. SHODELL M, SIEGAL FP: Corticosteroids depress IFN-alpha-producing plasmacytoid dendritic cells in human blood. J Allergy Clin Immunol 2001; 108: 446-8.
26. RADSTAKE TR, van LENT PL, PESMAN GJ et al.: High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering. Ann Rheum Dis 2004; 63: 696-702.
27. CUROTTO de LAFAILLE MA, LAFAILLE JJ: CD4(+) regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 2002; 14: 771-8.
28. JONULEIT H, SCHMITT E, STEINBRINK K, ENK AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001; 22: 394-400.
29. CRISPIN JC, VARGAS MI, ALCOCER-VARELA J: Immunoregulatory T cells in autoimmunity. Autoimmun Rev 2004; 3: 45-51.
30. van AMELSFORT JM, JACOBS KM, BIJLSMA JW. LAFEBER FP, TAAMS LS: CD4(+) CD 25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004; 50: 2775-85.
31. MAURER D, FELZMANN T, HOLTER W, PETERA P, SMOLEN J, KNAPP W: Evidence for the presence of activated CD4 T cells with naive phenotype in the peripheral blood of patients with rheumatoid arthritis. Clin Exp Immunol 1992; 87: 429-34.
32. EHRENSTEIN MR, EVANS JG, SINGH A et al.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200: 277-85.
33. MAURICE MM, van der GRAAFF WL, LEOW A, BREEDVELD FC, van LIER RA, VERWEIJ CL: Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 2166-73.
34. LORENZ HM, ANTONI C, VALERIUS T et al.: In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996; 156: 1646-53.
35. TAK PP. TAYLOR PC, BREEDVELD FC et al.: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077-81.